



Forbion Promotes Mathias Vinther, PhD to Partner within its Growth Strategy

Naarden, The Netherlands – 21 October 2025 - Forbion is pleased to announce the promotion of Mathias Vinther, PhD to Partner within its Growth Fund. Mathias joined Forbion in March 2022 as Principal, and has been instrumental in the evaluation, development, and support of numerous growth-stage biotech opportunities. During his time at Forbion, he has led due diligence on opportunities across Europe and the United States, supported portfolio companies such as Navigator, Vectiv Bio, and Capstan on business and regulatory strategy, and contributed to several successful exits and IPOs.

As Partner, Mathias will play an expanded leadership role in shaping the strategy for the Growth Fund, making investment decisions, guiding portfolio companies, and strengthening Forbion's network of scientific and industry relationships.

Commenting on the promotion, **Dirk Kersten, Managing Partner** at Forbion said, "Mathias has distinguished himself through his deep science-driven investment approach and his commitment to scaling companies that deliver meaningful patient impact. We are delighted to elevate him to Partner and look forward to his leadership in driving the Growth team's next phase."

Mathias added, "It's an honour to take on the role of Partner at Forbion. The Growth team is in a strong position to partner with outstanding companies in Europe and the U.S. that are developing the next generation of therapies. I look forward to working with our entrepreneurs, leveraging our experience and resources to help them succeed."

Mathias holds a PhD in Nanomedicine from Aarhus University, where his research focused on immunotherapy and drug delivery, and he has conducted additional studies at UC Berkeley and Harvard Medical School.

*****ENDS*****

Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm's team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.